NEW YORK (Reuters Health) April 16 Pentoxifylline therapy provides only limited efficacy against recurrent aphthous stomatitis and should not be considered a first-line agent, new research indicates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results